Before GLP: The Value of Robust Exploratory Toxicology

Chris Ryan is Senior Director of Business Development with Frontage Laboratories, Inc. supporting non-clinical safety and toxicology and drug metabolism and pharmacokinetics (’DMPK’) for pharma and biotech clients’ drug development programs. Mr. Ryan has worked for several Contract Research Organizations in drug development for over 18 years. As a former project manager for IND-directed programs, he has helped dozens of companies work through the complexities of pre-clinical safety and toxicology programs.